Elsevier

The Lancet

Volume 279, Issue 7243, 23 June 1962, Pages 1323-1326
The Lancet

ORIGINAL ARTICLES
EXPERIMENTAL EVALUATION OF AN ORALLY ACTIVE COMBINATION OF ANDROSTERONE WITH ETHYL CHLOROPHENOXYISOBUTYRATE

https://doi.org/10.1016/S0140-6736(62)92423-6Get rights and content

First page preview

First page preview
Click to open first page preview

References (2)

  • ICI 28,257: U.K. patent no....
  • ICI 28,257/A: U.K. patent application no....

Cited by (106)

  • Medicinal chemistry and pharmacology of statins

    2022, Cholesterol: From Chemistry and Biophysics to the Clinic
  • Fibrates inhibit aldose reductase activity in the forward and reverse reactions

    2005, Biochemical Pharmacology
    Citation Excerpt :

    Furthermore, AR has been implicated in diabetic autonomic neuropathy (DAN) that has an increased cardiovascular mortality rate compared with patients without DAN [13]. Fibrates (Fig. 1) were developed and effectively used clinically to treat dyslipidemia [14–16]. Studies in rodents and humans reveal major mechanisms that are implicated in the modulation of lipoprotein phenotypes by fibrates through the activation of PPARα[17–27].

View all citing articles on Scopus
View full text